journal: Advances in Laboratory Medicine / Avances en Medicina de Laboratorio

Impact Factor: 1.0

Open Access Published since February 20, 2020

Advances in Laboratory Medicine / Avances en Medicina de Laboratorio

Official Journal of the Spanish Society of Laboratory Medicine SEQC-ML

ISSN: 2628-491X

Editor-in-chief: Álvaro González Hernández

Edited by: Ignacio Arribas Gómez, Ángel Díaz Lagares, Pilar Fernandez Calle, Anna Merino González, Wladimiro Jiménez Povedano

Submit manuscript

About this journal

Objective: Advances in Laboratory Medicine / Avances en Medicina de Laboratorio (Adv Lab Med) is the official journal of the Spanish Society of Laboratory Medicine (SEQC^ML). Adv Lab Med publishes contributions in the field of medical sciences, including Biochemistry, Hematology, Toxicology, Microbiology and Parasitology, Immunology, and Genetics. Articles focusing on the choice, performance or interpretation of clinical tests are especially welcome.
Adv Lab Med publishes quarterly. All contributions submitted for publication in Adv Lab Med are single-blind peer reviewed by at least two experts in the field, selected and invited by the Editor-in-Chief. Adv Lab Med is an Open Access journal with an international board of renowned editors. Authors are not charged for manuscript processing and Open Access publication. SEQC^ML covers processing and publication charges. The Society plays no role in the selection and publication of the articles, nor does it influence peer review. Adv Lab Med is a bilingual journal, and all articles are published in both English and Spanish.

Please submit your manuscript here

Submissions in the following fields are welcome:

Clinical Chemistry / Clinical Hematology and Coagulation / Genetic and Molecular Biology / Clinical Immunology and Autoimmunity / Clinical Microbiology and Parasitology / Drug Monitoring and Toxicology / Evaluation of Diagnostic Biomarkers / New Technologies and Methodologies / Reference Materials and Methods / Reference Values and Decision Limits / Quality Control / Translational Laboratory Medicine / Endocrinology and Metabolism / Lipids and Lipoproteins / Cardiovascular Risk Factors / Cancer Biomarkers / Clinical Metrology / Laboratory Management / POCT

Article Formats

Research Articles: full length articles and short communications / Reviews and Mini Reviews / Opinion Papers / Editorials / Letters to the Editor and Replies / Case Reports / Guidelines and Recommendations

The journal Advances in Laboratory Medicine invites submissions for a special issue on liquid biopsy

We welcome papers that address new aspects related to clinical laboratory analytics and their applications in the diagnosis, monitoring and evaluation of medical treatments. The deadline for submission is 30 October 2024.

The scientific journal Advances in Laboratory Medicine, launched by SEQC^ML in February 2020, encourages our scientific community to contribute to our upcoming special issue on Liquid Biopsy and its applications in the diagnosis, monitoring, and evaluation of medical treatments. Contributing authors should focus on the current state-of-affairs of circulating DNA analysis techniques applied to cancer, genetic, and metabolic diseases and prenatal diagnosis. Papers on the combined use of DNA analysis and other biochemical, molecular and imaging studies are also be welcome.

The term 'liquid biopsy' is primarily used in the field of cancer diagnostics. These tests provide a picture of the characteristics of the tumor from a sample of biological fluid, primarily blood, which contains multiple tumor-released analytes, including circulating cell-free DNA. This DNA is produced by tumor and non-tumor cells that necrotize, undergo apoptosis, and release DNA into the bloodstream. Liquid biopsy is minimally invasive and more cost-effective than conventional biopsy. It is also an indicator of tumor heterogeneity and, in some cases, is useful for monitoring disease response and/or resistance to treatment. In any case, being based on the analysis of biological fluids, liquid biopsy is very similar to other tests long performed in the clinical laboratory.

Liquid biopsy is primarily used for the management of cancer. It involves the analysis of several tumor-released analytes, including circulating cell-free DNA and RNA, circulating tumor cells (CTCs), and extracellular vesicles (EVs), to name a few. Liquid biopsy enables the detection of specific abnormalities, translocations and even deficient DNA methylation. However, this technique is not only used in the field of cancer, but it is also useful for non-invasive prenatal diagnosis, with a potentially significant clinical and social impact. Fetal circulating cell-free DNA can be detected in peripheral blood since the first trimester of pregnancy, which renders this technique a very powerful prenatal diagnostic tool. In addition, liquid biopsy overcomes the drawbacks of amniotic fluid or chorionic villus sampling. The activity of oncogenes and tumor suppressor genes determines whether a specific cell acquires the properties of cancer. Thus, liquid biopsy can help determine whether a genetic mutation corresponds to an oncogene or a tumor suppressor gene. In addition, this technique has the potential to identify different clinical situations by the type of mutation. Variations may be found in single nucleotide, insertions, genomic insertions or deletions, fusions and variations in the number of copies. Analytical and instrumental approaches are also relevant, including targeted therapies or strategies based on the so-called 'omics', i.e. massive sequencing. In all cases, liquid biopsy requires a more or less complex bioinformatic analysis.

The applications of circulating cell-free DNA in diseases other than cancer are also gaining popularity. This strategy has been documented to be useful in myocardial infarction and stroke, as well as a biomarker of organ transplant rejection, or as a prognostic factor in pancreatic islet transplantation. Other systems have been developed for specific applications such as population-based prenatal screening in the first trimester of pregnancy. This screening involves the analysis of circulating cell-free fetal DNA in maternal blood. It should be noted that the preanalytical conditions of liquid biopsy are critical (crucial) for the reliability of the results. In conclusion, liquid biopsy has been proven to be a minimally-invasive tool with multiple applications in a wide range of diseases and clinical contexts.

Manuscripts should be submitted to Advances in Laboratory Medicine at https://mc.manuscriptcentral.com/almed before October 30th, 2024. Please indicate in your Letter to the Editors (cover letter) that your paper is submitted for the special issue on Liquid Biopsy. Following approval, all manuscripts will be peer-reviewed and published immediately in our journal. Research papers, reviews and short communications are of special interest.

You can find the Instructions for Authors here.

Your Benefits

Latest developments in the clinical laboratory sciences
Fundamental and applied approach
Novel teaching and training methods
High quality peer-review
No Article Processing Charge
Publication under the Creative Commons Attribution (CC-BY-4.0) License
Free translation of each article into Spanish or English

History

Advances in Laboratory Medicine / Avances en Medicina de Laboratorio was founded by the Spanish Society of Laboratory Medicine (SEQC^ML), and launched at EuroMedLab 2019 in Barcelona.

Other publications in the field

Abstracting and Indexing

Advances in Laboratory Medicine / Avances en Medicina de Laboratorio is covered by the following services:

Baidu Scholar
CABI (over 50 subsections)
Chronos Hub
CNKI Scholar (China National Knowledge Infrastructure)
CNPIEC - cnpLINKer
Dimensions
DOAJ (Directory of Open Access Journals)
EBSCO Discovery Service
Google Scholar
J-Gate
KESLI-NDSL (Korean National Discovery for Science Leaders)
MyScienceWork
Naver Academic
Naviga (Softweco)
Primo Central (ExLibris)
PubMed
PubMed Central
ReadCube
Scilit
SCImago (SJR)
SCOPUS
Semantic Scholar
Summon (ProQuest)
TDNet
WanFang Data
Web of Science - Emerging Sources Citation Index
WorldCat (OCLC)
X-MOL
Yewno Discover

Supplementary Materials

Topics

External Links

Ahead of Print / Just Accepted

Ahead of Print / Just Accepted

Volume 5 (2024)

Issue 1 Special Issue on Bone Biomarkers / Edición Especial sobre Marcadores Óseos

Volume 4 (2023)

Volume 3 (2022)

Volume 2 (2021)

Volume 1 (2020)

Recent Special Issues

Special Issue on Bone Biomarkers / Edición Especial sobre Marcadores Óseos [Issue 1, Volume 5 (2024)]

Journal Impact Factor	1.0	2022, Journal Citation Reports (Clarivate, 2023)
5-year Journal Impact Factor	1.0	2022, Journal Citation Reports (Clarivate, 2023)
Journal Citation Indicator	0.19	2022, Journal Citation Reports (Clarivate, 2023)
CiteScore	0.7	2022, Scopus (Elsevier B.V., 2023)
SCImago Journal Rank	0.199	2022, SJR (Scimago Lab, 2023; Data Source: Scopus)
Source Normalized Impact per Paper	0.281	2022, CWTS Journal Indicators (CWTS B.V., 2023; Data Source: Scopus)

More information about journal rankings

Submit

Submission

You can easily submit your manuscript online. Simply go to http://mc.manuscriptcentral.com/almed and you will be guided through the whole submission and publishing process.

Your benefits of publishing with us

Rapid publication times
No submission fee
No article processing charge (APC)
Open Access - research freely available for all to read and download
Authors retain copyright – articles published under the Creative Commons Attribution (CC-BY-4.0) License
Free translation of each article into Spanish or English funded by unrestricted education grant
Every article easily discoverable because of SEO and comprehensive abstracting and indexing services
Secure archiving by De Gruyter and the independent archiving service Portico

Submission process

Submission of your manuscript via our submission management tool following the Information for Authors
Single-blind peer review process
A decision on your paper is aspired within 3-4 weeks
Accepted articles are published online ahead of print approx. 4 weeks after acceptance

Please note

Manuscripts must be written in clear and concise English or Spanish
Before submitting your article please have a look at the Submission Checklist and Publication Ethics Statement
The License to Publish must be filled in and signed, and submitted as separate file
As a condition of submission, the Template for Ethical and Legal Declarations (ENGLISH or SPANISH) must be customized by the submitting author on behalf of all others and uploaded as a separate Word file. Instructions on how to make declarations can be found here
If you have any general questions please visit our FAQ page for authors
For more detailed information please contact the Editorial Office editorial.office@seqc.es

We look forward to receiving your manuscript!

Editorial

Editor-in-Chief
Álvaro González Hernández, Clínica Universidad de Navarra, Pamplona, Spain
agonzaleh@unav.es

Associate Editors
Ignacio Arribas Gómez, Hospital Universitario Ramón y Cajal, Madrid, Spain
arribasignacio@gmail.com

Ángel Díaz Lagares, Complejo Hospitalario Universitario de Santiago de Compostela (CHUS), Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS) CIBERONC, Santiago de Compostela, Spain
Angel.Diaz.Lagares@sergas.es

Pilar Fernández Calle, Hospital La Paz, Madrid, Spain
pfernandez.hulp@gmail.com

Anna Merino González, Hospital Clínic, Barcelona, Spain
amerino@clinic.es

Wladimiro Jiménez Povedano, Universitat de Barcelona, Barcelona, Spain
wjimenez@clinic.cat

Advisory Board
Mª Belén Aparicio Hernández, Hospital Universitario de Salamanca, Salamanca, Spain
salaautoinmunidad@yahoo.es

Hugo Azevedo Rocha, Instituto Nacional de Saude Ricardo Jorge, Porto, Portugal
hugodanielrocha@netcabo.pt

Antonio Buño Soto, Hospital La Paz, Madrid, Spain
antoniobuno@gmail.com

María José Calasanz Abinzano, Universidad de Navarra, Pamblona, Spain
mjcal@unav.es

Francesca Canalias Reverter, Universitat Autònoma de Barcelona, Barcelona, Spain
francesca.canalias@uab.cat

Edgardo Carosella, Hemato-Immunology Research Department, CEA, Hospital Saint Louis, Paris, France
edgardo.carosella@cea.fr

Patrocinio Chueca Rodríguez, SEQC-ML, Comite de Comunicacion, Navarra, Spain
patrochueca@gmail.com

Abdurrahman Coskun, Ali Aydinlar University, Istanbul, Turkey
coskun2002@gmail.com

Ana Belén Crujeiras, Complejo Hospitalario Universitario de Santiago de Compostela (CHUS), Santiago de Compostela, Spain
anabelencrujeiras@hotmail.com

Amitava Dasgupta, University of Texas McGovern Medical School at Houston and Laboratory Services, Memorial-Hermann Hospital at Texas Medical Center, Houston, TX, USA
Amitava.Dasgupta@uth.tmc.edu

Miguel Fernández de Sanmamed Gutiérrez, Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA
msanmamed@unav.es

Maurizio Ferrari, Vita-Salute San Raffaele University, Milan, Italy
ferrari.maurizio@hsr.it

Xavier Filella Pla, Hospital Clínic, Barcelona, Spain
xfilella@clinic.cat

Callum G. Fraser, University of Dundee, Dundee Scotland, UK
callum.fraser@nhs.net

Rubén Gómez Rioja, Hospital La Paz, Madrid, Spain
rgrioja@salud.madrid.org

Montserrat González Estecha, Hospital Clínico San Carlos, Madrid, Spain
MONTSE@CMPX.NET

Damien Gruson, Cliniques universitaires Saint-Luc, Brussels, Belgium
damien.gruson@uclouvain.be

Eva Guillén Campuzano, President of the Scientific Committee of SEQC^ML, Barcelona, Spain
eguillen@catlab.cat

Joao Tiago Guimaraes, University of Porto, Porto, Portugal
jtguimar@med.up.pt

Anatoli Horuzsko, Georgia Cancer Center at Augusta University, Augusta, GA, USA
ahoruzsko@augusta.edu

Mercè Ibarz Escuer, Hospital U. Arnau de Vilanova, Lleida, Spain
mibarz.lleida.ics@gencat.cat

Eric S. Kilpatrick, Sidra Medical and Research Center, Doha, Qatar
kilpatricks@cshs.org

Giuseppe Lippi, University Hospital of Verona, Verona, Italy
giuseppe.lippi@univr.it

Eva Martínez Cáceres, Hospital Germans Trias i Pujol Badalona, Barcelona, Spain
emmartinez.germanstrias@gencat.cat

Anna Merino González, Hospital Clínic, Barcelona, Spain
amerino@clinic.ub.es

Manuel Morales Ruiz, Hospital Clínic. Barcelona, Barcelona, Spain
morales@clinic.cat

Miguel Angel Moreno Pelayo, Hospital Universitario Ramón y Cajal, Madrid, Spain
mmorenop@salud.madrid.org

Michael Neumaier, Medical Faculty Mannheim of Heidelberg University, Mannheim, Germany
michael.neumaier@medma.uni-heidelberg.de

Josep Oriola Ambrós, Hospital Clínic, Barcelona, Spain
joriola@clinic.ub.es

Alberto Pérez-Mediavilla, Universisad de Navarra, Pamplona, Spain
lamediav@unav.es

Mario Plebani, University Hospital Padova, Padova, Italy
mario.plebani@unipd.it

Belén Prieto García, Hospital Universitario Central de Asturias, Oviedo, Spain
prietobelen7@gmail.com

Jose Puzo Foncillas, Hospital General San Jorge, Huesca, Spain
JPUZO@UNIZAR.ES

Rodolfo Alberto Rey, University of Buenos Aires, Buenos Aires, Argentina
rodolforey@cedie.org.ar

Carmen Ricós Águila, Quality Commission, SEQC^ML, Barcelona, Spain
cricosaguila@gmail.com

Francisco Rodriguez Frias, Hospital Vall d'Hebron, Barcelona, Spain
frarodriguez@vhebron.net

Sverre Sandberg, Haukeland University Hospital, Bergen, Norway
sverre.sandberg@noklus.no

Ana-Maria Šimundić, Clinical Hospital Sveti Duh Zagreb, Zagreb, Croatia
am.simundic@gmail.com

Christos Tsatsanis, University of Crete Medical School, Heraklion, Greece
tsatsani@uoc.gr

Rafael Venta Obaya, Hospital San Agustín, Asturias, Spain
rafael.venta@sespa.es

Franz Villarroel Espindola, Fundación Arturo López Pérez, Providencia, Chile
franz.villarroel@falp.org

Ian Young, Queen’s University Belfast, Belfast, UK
i.young@qub.ac.uk

Inès Zidi, University of Tunis El Manar, Tunis, Tunisia
ines.zidi@istmt.utm.tn

Managing Editors
Roser Ferrer Costa, Hospital Universitari Vall d'Hebron, Barcelona, Spain
roser.ferrer@vallhebron.cat

Albert Bastias González, Barcelona, Spain
editorial.office@seqc.es

Editorial Office
Heike Jahnke
De Gruyter
Genthiner Str. 13
10785 Berlin
Germany
E-mail: Heike.Jahnke@degruyter.com

Volume 5 Issue 1

March 2024

Publicly Available April 17, 2024

Frontmatter

Page range: i-ii

Download PDF

Editorial

Open Access February 27, 2024

Bone remodeling markers: monitoring the changing bone

Nerea Varo

Page range: 1-3

Download PDF

Open Access February 21, 2024

Marcadores de remodelado óseo, monitorizar el cambiante hueso

Nerea Varo

Page range: 4-6

Download PDF

Review / Artículo de Revisión

Open Access August 28, 2023

Clinical use of bone markers: a challenge to variability

Xavier Filella, Núria Guañabens

Page range: 7-14

More Download PDF

Abstract

Bone markers are a group of substances released into circulation during bone formation and/or resorption. These substances can be measured in blood and urine to obtain information about metabolic bone disorders. This review provides an insight into factors influencing bone marker variability and describes different approaches to minimize variability and interpret results appropriately. Variability in bone marker concentrations results from biological and analytical variability across assays. Other influencing factors include gender, age, physical exercise, circadian rhythm, and diet. The multiplicity of influencing factors hinders the establishment of accurate reference values. Gaining a deep understanding of bone marker variability is the first step to ascertain their clinical usefulness. Bone marker variability can be minimized by controlling as many variables as it is possible and through the standardization of patient preparation and sample collection and handling.

Open Access July 24, 2023

Utilidad clínica de los biomarcadores óseos: un desafío a la variabilidad

Xavier Filella, Núria Guañabens

Page range: 15-23

More Download PDF

Abstract

Resumen Los biomarcadores óseos son un conjunto de sustancias que son liberadas a la circulación sanguínea durante el proceso de formación y/o resorción ósea y que podemos medir en sangre y orina para obtener información sobre los trastornos metabólicos del hueso. La revisión traza una perspectiva sobre los factores que influyen en la variabilidad de los biomarcadores óseos y describe los aspectos a considerar para reducirla al máximo e interpretar los resultados de manera adecuada. La variabilidad que podemos observar en la concentración de los biomarcadores óseos engloba diversos aspectos que abarcan desde su variabilidad biológica y la variabilidad de los ensayos empleados en su medida hasta la variabilidad derivada de la influencia de numerosos factores, entre los cuales el sexo, la edad, el ejercicio, su ritmo circadiano o la dieta. Todo ello se refleja en la dificultad de establecer valores de referencia precisos. El conocimiento de esta variabilidad es el primer desafío que debe afrontar su empleo en la práctica clínica. Es necesario minimizar la variabilidad de los biomarcadores óseos controlando el máximo de variables que sea posible, así como estandarizando la preparación del paciente antes de la toma de las muestras, así como su obtención y manejo.

Open Access December 12, 2023

The hidden cross talk between bone and tissues through bone turnover

María Luisa González-Casaus

Page range: 24-34

More Download PDF

Abstract

Bone is more than a reservoir of calcium and phosphorus. Its lacuno-canalicular arrangement provides an important pathway for exchange with circulation and currently, the skeleton is considered a large endocrine organ with actions that go beyond the control of calcium-phosphorus balance mediated by fibroblastic growth factor 23 (FGF23). Parallel to the modulating effect of adipokines on bone turnover, certain bone proteins, such as osteocalcin and sclerostin, play a counter-regulatory role on energy metabolism, probably in an attempt to ensure its high energy requirement for bone turnover. In this crosstalk between bone and other tissues, especially with adipose tissue, canonical Wnt/β-catenin signaling is involved and therefore, sclerostin, an osteocyte derived protein that inhibits this signalling, emerges as a potential biomarker. Furthermore, its involvement in diverse pathologic conditions supports sclerostin as a therapeutic target, with an anti-sclerostin antibody recently approved in our country for the treatment of osteoporosis. This review addresses the endocrine nature of bone, the role of osteocalcin, and specially, the regulatory and modulatory role of sclerostin on bone turnover and energy homeostasis through its inhibitory effect on canonical Wnt/β-catenin signaling, as well as its potential utility as a biomarker.

Open Access September 22, 2023

El diálogo oculto entre el hueso y los tejidos a través del remodelado óseo

María Luisa González-Casaus

Page range: 35-45

More Download PDF

Abstract

Resumen El hueso es mucho más que un reservorio de calcio y fósforo. Su disposición lacuno-canalicular ofrece una importante vía de intercambio con la circulación y actualmente, el esqueleto se considera un gran órgano endocrino, con acciones que van más allá del control del balance fosfocálcico mediado por el factor fibroblástico 23 (FGF23). Paralelamente al efecto modulador de las adipoquinas sobre el remodelado óseo, diversas proteínas óseas, como la osteocalcina y la esclerostina, ejercen cierta acción contra-reguladora sobre el metabolismo energético, posiblemente en un intento de asegurar los enormes requerimientos energéticos del remodelado. En esta interacción del hueso con otros tejidos, especialmente el adiposo, participa la señalización canónica Wnt/β-catenina y por ello la esclerostina, una proteína osteocítica que inhibe esta señalización, emerge como un potencial biomarcador. Es más, su participación en diversas patologías le posiciona como diana terapéutica, existiendo un anticuerpo anti-esclerostina, recientemente aprobado en nuestro país para el tratamiento de la osteoporosis. Esta revisión aborda el carácter endocrino del hueso, el papel de la osteocalcina y, especialmente, el papel regulador y modulador de la esclerostina sobre remodelado óseo y la homeóstasis energética a través de su interacción con la señalización canónica Wnt/β-catenina, así como su potencial utilidad como biomarcador.

Original Article / Artículo Original

Open Access October 24, 2023

Osteocalcin associates with bone mineral density and VDR gene polymorphisms in type 1 and type 2 diabetes

Carla Ramírez Ruiz, Nerea Varo Cenarruzabeitia, Miriam Martínez Villanueva, Antonio M. Hernández Martínez, José Antonio Noguera Velasco

Page range: 46-55

More Download PDF

Abstract

Objectives Bone metabolism is impaired in diabetes mellitus (DM). Our objective is to evaluate the association of bone turnover markers (BTM) and vitamin D receptor ( VDR ) gene polymorphisms with bone mineral density (BMD) in DM type 1 (T1D) and DM type 2 (T2D). Methods A total of 165 patients (53 T1D and 112 T2D) were enrolled. BMD was measured by dual-energy X-ray absorptiometry (DEXA). Plasma osteocalcin (OC), beta-CrossLaps (β-CTX) and N‐amino terminal propeptide of type I collagen (P1NP) and VDR gene polymorphisms were evaluated. Results Participants were 53 T1D (41 years [31–48]) and 112 T2D (60 years [51–66]). BMD were not statistically different between the groups. OC (p<0.001) and P1NP levels (p<0.001) were higher in patients with T1D. The areas under the curve for the prediction of bone pathology were 0.732 (p=0.038) for OC in T1D and 0.697 (p=0.007) in T2D. A significant association was found between lower lumbar BMD and the A allele of BsmI (p=0.03), the A allele of ApaI (p=0.04) and the allele C of the Taql (p=0.046). Also, a significant correlation was found with higher OC levels and the G allele of BsmI (p=0.044), C allele of ApaI (p=0.011), T allele of Taql (p=0.006) and with C allele of FokI (p=0.004). Conclusions The high negative predictive value of the cut-off point for OC suggests that could be useful in excluding the risk suffering bone loss, allowing offering a personalized clinical approach to prevent this pathology.

Open Access December 13, 2023

La osteocalcina se asocia con la densidad mineral ósea y los polimorfismos del gen VDR en la diabetes tipo 1 y 2

Carla Ramírez Ruiz, Nerea Varo Cenarruzabeitia, Miriam Martínez Villanueva, Antonio M. Hernández Martínez, José A. Noguera Velasco

Page range: 56-65

More Download PDF

Abstract

Resumen Objetivos El metabolismo óseo se encuentra alterado en la diabetes mellitus (DM). El objetivo de este estudio es evaluar la relación entre los marcadores de remodelado óseo (MRO), los polimorfismos en el gen receptor de la vitamina D ( VDR ) y la densidad mineral ósea (DMO) en la DM tipo 1 (T1D) y tipo 2 (T2D). Métodos Se incluyó a 165 pacientes (53 T1D y 112 T2D). La DMO se midió mediante absorciometría de rayos X de energía dual (DEXA). Se realizó un análisis de la osteocalcina (OC) en plasma, beta-CrossLaps (β-CTX), propéptido aminoterminal del procolágeno tipo 1 (P1NP) y los polimorfismos en el gen VDR . Resultados Se incluyó a 53 pacientes con T1D (41 años (31–48)) y 112 con T2D (60 años [51–66]). No se observaron diferencias estadísticamente significativas en relación a la DMO. Los pacientes con T1D presentaron niveles superiores de OC (p<0,001) y P1NP (p<0,001). Las áreas bajo la curva para la predicción de patología ósea para la OC fueron 0,732 (p=0,038) en T1D y 0,697 (p=0,007) en T2D. Se observó una relación estadísticamente significativa entre el alelo A de BsmI (p=0,03), el alelo A de ApaI (p=0,04) y el alelo C de Taql (p=0,046) y una menor DMO. Así mismo, se encontró una correlación significativa entre los niveles elevados de OC y el alelo G de BsmI (p=0,044), el alelo C de ApaI (p=0,011), el alelo T de Taql (p=0,006) y el alelo C de FokI (p=0,004). Conclusiones El elevado valor predictivo negativo del punto de corte de la OC indica que la OC podría ser útil a la hora de descartar el riesgo de pérdida ósea, lo que permitiría diseñar un tratamiento personalizado para prevenir dicha patología.

Open Access March 8, 2024

Bone metabolism in children with normal weight and overweight/obesity in a northeastern region of Spain

José Cuenca Alcocel, Lorena Villalba-Heredia, Inés Martínez Redondo, Clara Berrozpe-Villabona, José Antonio Casajús, José Miguel Arbonés-Mainar, Pilar Calmarza

Page range: 66-74

More Download PDF

Abstract

Objectives Bone mass progressively increases to peak during childhood and adolescence, which determines future bone health. Bone formation–resorption processes are assessed using bone markers. However, studies on the impact of obesity on bone turnover markers at this age are limited, and results are inconsistent. The objective of this study was to examine the potential impact of overweight/obesity on bone metabolism. Methods A study was performed to compare parameters of bone metabolism in 45 girls and boys with normal weight (controls) and in a group of 612 girls and boys with overweight/obesity (cases) from the Exergames study (University of Zaragoza). Ages ranged from 8 to 12 years. Results Higher values of phosphorus and IGFBP-3 were observed in children with overweight/obesity, as compared to children with normal weight, (p=0.042) and (p=0.042), respectively. BAP, osteocalcin, magnesium, vitamin D and IGF-I concentrations were lower in the group with overweight/obesity, whereas calcium concentrations were higher in this group, although differences were not statistically significant. A negative correlation was found (r=−0.193) (p=0.049) between BAP and BMI. Conclusions Although differences did not reach statistical significance, BAP and osteocalcin concentrations were lower in children with overweight/obesity. This added to the negative correlation found between BAP and MIC may demonstrate that overweight/obesity may negatively affect bone health already at a young age.

Open Access January 1, 2024

Metabolismo óseo en niños aragoneses con normopeso y niños con sobrepeso/obesidad

José Cuenca Alcocel, Lorena Villalba-Heredia, Inés Martínez Redondo, Clara Berrozpe-Villabona, José Antonio Casajús, José Miguel Arbonés-Mainar, Pilar Calmarza

Page range: 75-84

More Download PDF

Abstract

Resumen Objetivos En la infancia y adolescencia se produce un aumento de masa ósea, hasta alcanzar un pico máximo, determinante para la salud ósea. Los marcadores óseos evalúan los procesos de formación-resorción ósea. Sin embargo, los estudios sobre la influencia de la obesidad en los marcadores de recambio óseo en esta edad, son escasos y los resultados contradictorios. El objetivo de nuestro estudio fue evaluar si el sobrepeso/obesidad influían en el metabolismo óseo. Métodos Se compararon parámetros relacionados con el metabolismo óseo, en 45 niños y niñas normopeso (controles) y en un grupo de 61 niños y niñas con sobrepeso/obesidad (casos), procedentes del estudio Exergames (Universidad de Zaragoza), de edades comprendidas, todos ellos, entre 8 y 12 años. Resultados La concentración de fósforo y la de IGFBP-3 fueron superiores en los niños con sobrepeso/obesidad, respecto a la de los niños normopeso, (p=0,042) y (p=0,042), respectivamente. Las concentraciones de BAP, osteocalcina, magnesio, vitamina D e IGF-I fueron más bajas en el grupo de los niños con sobrepeso/obesidad y la de calcio más elevada, pero las diferencias no fueron estadísticamente significativas. Existe correlación negativa (r=−0,193) (p=0,049) entre BAP e IMC. Conclusiones En los niños con sobrepeso/obesidad pese a que no se llegó a alcanzar significación estadística, la concentración de BAP y osteocalcina fue inferior a la de los niños normopeso, lo cual junto con la correlación negativa de BAP respecto al IMC encontrada, puede indicar que ya en edades tan tempranas el sobrepeso/obesidad puede afectar a la salud ósea.

Open Access March 25, 2024

Estudio del efecto del tratamiento con fármacos antidiabéticos sobre el metabolismo óseo

Nuria Padilla Apuntate, Carmen G. Puerto Cabeza, Alba Gallego Royo, Nuria Goñi Ros, Claudia Abadía Molina, Javier Acha Pérez, Pilar Calmarza

Page range: 90-95

More Download PDF

Abstract

Resumen Objetivos La prevalencia de la diabetes mellitus tipo 2 (DMT2) está aumentando de forma exponencial en todo el mundo, habiéndose comprobado que estos pacientes tienen mayor riesgo de presentar fracturas óseas, con respecto a la población sana, por lo que resulta de gran relevancia el conocimiento del efecto de los fármacos antidiabéticos sobre el metabolismo óseo. Métodos Estudio estadístico descriptivo, retrospectivo, de 106 pacientes en tratamiento con seis grupos de fármacos antidiabéticos: insulina, inhibidores de dipeptidilpeptidasa 4 (iDPP4), agonistas del receptor del péptido similar al glucagón tipo 1 (arGLP1), sulfonilureas, inhibidores del cotransportador de sodio-glucosa tipo 2 (iSGLT2) y pioglitazona, en los que se determinaron osteocalcina (OC), fosfatasa alcalina ósea (FAO) y telopéptido C-terminal del colágeno tipo 1 o beta-crosslaps (β-CTx). Resultados Se encontraron concentraciones más elevadas de β-CTx en los pacientes tratados con pioglitazona que en los tratados con iDPP4 (p=0,035), iSGLT2 (p=0,020) y con arGLP1 (p<0,001), siendo los pacientes tratados con arGLP1 los que presentaron las concentraciones más bajas de β-CTx. Conclusiones El tipo de tratamiento antidiabético recibido en pacientes que padecen DMT2 puede afectar el remodelado óseo. En nuestro estudio los pacientes que fueron tratados con pioglitazona mostraron las concentraciones más elevadas de β-CTx con respecto al resto de grupos de fármacos, lo cual parece indicar la conveniencia de evitar estos fármacos, sobre todo en mujeres postmenopáusicas con DMT2. Los fármacos arGLP1 presentaron los valores más bajos de β-CTx, por lo que podrían ejercer un efecto beneficioso sobre el metabolismo óseo.

Open Access April 3, 2024

Effects of antidiabetic drugs on bone metabolism

Nuria Padilla Apuntate, Carmen G. Puerto Cabeza, Alba Gallego Royo, Nuria Goñi Ros, Claudia Abadía Molina, Javier Acha Pérez, Pilar Calmarza

Page range: 85-89

More Download PDF

Abstract

Objectives The prevalence of diabetes mellitus type 2 (DMT2) is increasing exponentially worldwide. DMT2 patients have been found to be at a higher risk for bone fractures than the healthy population. Hence, improving our understanding of the impact of antidiabetic drugs on bone metabolism is crucial. Methods A descriptive, retrospective study involving 106 patients receiving six groups of antidiabetic drugs: insulin; dipeptidylpeptidase four inhibitors (DPP4i); glucagon-like peptide type 1 receptor agonists (GLP1ra); sulfonylureas; sodium-glucose cotransporter two inhibitors (SGLT2i); and pioglitazone, in which osteocalcin (OC), bone alkaline phosphatase (BAP) and C-terminal telopeptide of collagen type 1 or beta-crosslaps (β-CTx) were determined. Results β-CTx concentrations were higher in the patients treated with pioglitazone, as compared to patients treated with DPP4i (p=0.035), SGLT2i (p=0.020) or GLP1ra (p<0.001). The lowest β-CTx concentrations were observed in the patients treated with GLP1ra. Conclusions Bone remodeling is influenced by the type of antidiabetic drug administered to DMT2 patients. In our study, the patients who received pioglitazone showed higher β-CTx concentrations, as compared to patients treated with other types of antidiabetic drugs. This finding highlights the convenience of avoiding these drugs, especially in postmenopausal women with DMT2. GLP1ra drugs were associated with the lowest β-CTx concentrations, which suggests that these agents could exert beneficial effects on bone metabolism.

(Deutsch)

View latest issue

Type: Journal
Languages: English, Spanish
Publisher: De Gruyter
First published: February 20, 2020
Publication Frequency: 4 Issues per Year
Audience: basic scientists, translational researchers, clinical researchers, industry scientists and professionals in the field of laboratory medicine